929622-08-2
929622-08-2 structure
- Name: Bavisant
- Chemical Name: (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone
- CAS Number: 929622-08-2
- Molecular Formula: C19H27N3O2
- Molecular Weight: 329.43700
- Catalog: Signaling Pathways GPCR/G Protein Histamine Receptor
- Create Date: 2017-08-29 10:37:37
- Modify Date: 2024-01-11 18:17:26
-
Bavisant (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. IC50 Value: Target: H3 receptorin vitro: Bavisant completed a phase II ADHD trial, but no results have been reported [1].in vivo: Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2 and -12.2 in the bavisant 1?mg/day, 3?mg/day and 10?mg/day groups, respectively; the change in the 10?mg/day group was not statistically superior to placebo (p=0.161), and hence statistical comparisons of the 1?mg/day and 3?mg/day groups with placebo based on a step-down closed testing procedure were not performed [2].Clinical trial: A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2
| Name | (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone |
|---|---|
| Synonyms |
(4-cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone
UNII-9827P7LFVH BAVISANT Bavisant [USAN:INN] |
| Description | Bavisant (JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. IC50 Value: Target: H3 receptorin vitro: Bavisant completed a phase II ADHD trial, but no results have been reported [1].in vivo: Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2 and -12.2 in the bavisant 1?mg/day, 3?mg/day and 10?mg/day groups, respectively; the change in the 10?mg/day group was not statistically superior to placebo (p=0.161), and hence statistical comparisons of the 1?mg/day and 3?mg/day groups with placebo based on a step-down closed testing procedure were not performed [2].Clinical trial: A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2 |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C19H27N3O2 |
|---|---|
| Molecular Weight | 329.43700 |
| Exact Mass | 329.21000 |
| PSA | 36.02000 |
| LogP | 1.25270 |
| Storage condition | 2-8℃ |
|
~92%
929622-08-2 |
| Literature: Allison, Brett D.; Carruthers, Nicholas I.; Grice, Cheryl A.; Letavic, Michael A. Patent: US2007/66821 A1, 2007 ; Location in patent: Page/Page column 9 ; US 20070066821 A1 |
| Precursor 1 | |
|---|---|
| DownStream 0 | |